Dr. Fatima Marok

Forschungsgebiet

Physiologie-basierte Pharmakokinetik (PBPK) Modellierung von Arzneistoff-Wechselwirkungen

Lebenslauf

Seit 12/2024: Postdoktorandin in der Klinischen Pharmazie

04/2019 – 12/2024: Doktorandin in der Klinischen Pharmazie

01/2019: Approbation zur Apothekerin

12/2018 – 03/2019: Wissenschaftliche Mitarbeiterin in der Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken

05/2018 – 10/2018: Praktisches Jahr in der Landmann Apotheke, Saarbrücken

11/2017 – 04/2018: Praktisches Jahr und Diplomandin in der Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken

10/2013 – 10/2017: Studium der Pharmazie, Universität des Saarlandes, Saarbrücken

07/2013: Abitur, Marie Luise Kaschnitz Gymnasium, Völklingen

Publikationen

Manuskripte

Kovar C, Loer HLH, Rüdesheim S, Fuhr LM, Marok FZ, Selzer D, Schwab M, Lehr T. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024. doi:10.1002/psp4.13146

Loer HLH, Kovar C, Rüdesheim S, Marok FZ, Fuhr LM, Selzer D, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2024;00:1-15.

Marok FZ, Wojtyniak JG, Selzer D, Dallmann R, Swen JJ, Guchelaar HJ, Schwab M, Lehr T. Personalized chronomodulated 5-fluorouracil treatment: A physiologically-based pharmacokinetic precision dosing approach for optimizing cancer therapy. Clin Pharmacol Ther. 2024; 10.1002/cpt.3181.

Fuhr LM, Marok FZ, Fuhr U, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit-drug interactions. Clin Pharmacol Ther. 2023;114(2):470-482.

Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023;00:1-14

Marok FZ, Wojtyniak J-G, Fuhr LM, Selzer D, Schwab M, Weiss J, Haefeli WE, Lehr T. A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug–drug interaction perpetrators. Pharmaceutics. 2023;15(2):679.

Fuhr LM, Marok FZ, Mees M, Mahfoud F, Selzer D, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic model of the CYP3A4 substrate felodipine for drug-drug interaction modeling. Pharmaceutics 2022;14(7):1474.

Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T. Novel models for the prediction of drug-gene interactions. Expert Opin on Drug Metab Toxicol 2021;17(11):1293-1310.

Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network. Pharmaceutics 2021;13(3):331.

Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and its drug-drug interaction potential: a physiologically based pharmacokinetic modeling approach. Pharmaceutics 2021;13(2):270.

Poster

Marok F, Wojtyniak JG, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine. 28th Population Approach Group Europe (PAGE) meeting, 2019, Stockholm, Sweden.

Marok F, Wojtyniak JG, Schwab M, Lehr T. Optimizing 5-fluorouracil chemotherapy with regard to DPD drug-gene interactions and circadian effects utilizing a physiologically based pharmacokinetic (PBPK) modeling approach. Annual Meeting of the German Pharmaceutical Society (DPhG), 2019, Heidelberg, Germany.